Atazanavir-d24

Atazanavir-d24 (BMS-232632-d24) is deuterium labeled Atazanavir. Atazanavir (BMS-232632) is a highly selective and orally active HIV-1 protease inhibitor . Atazanavir is a substrate and inhibitor of CYP3A4, and an inhibitor of P-glycoprotein (P-gp) . Atazanavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 3.49 μM. Atazanavir inhibits cardiac fibrosis, hyperlipidemia and induces malignant glioma death[1][2][3][4][5][6][7][8].

Product Specifications

CAS Number

[1092540-58-3]

Product Name Alternative

BMS-232632-d24

UNSPSC

12352005

Target

Cytochrome P450; Endogenous Metabolite; HIV; HIV Protease; Isotope-Labeled Compounds; P-glycoprotein; SARS-CoV; Toll-like Receptor (TLR)

Related Pathways

Anti-infection; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Others

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Cardiovascular Disease

Smiles

[2H]C([2H])([2H])OC(N[C@@H](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C(N[C@@H](CC1=CC=CC=C1)[C@@H](O)CN(NC([C@H](C(C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])NC(OC([2H])([2H])[2H])=O)=O)CC2=CC=C(C3=CC=CC=N3)C=C2)=O)=O

Molecular Formula

C38H28D24N6O7

Molecular Weight

729.00

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6 (6) :785-96.|[3]Havlir DV, et al. Atazanavir: new option for treatment of HIV infection. Clin Infect Dis. 2004 Jun 1;38 (11) :1599-604.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.|[5]Zhang G, et al. Long-term oral atazanavir attenuates myocardial infarction-induced cardiac fibrosis. Eur J Pharmacol. 2018 Jun 5;828:97-102.|[6]Fukushima K, et al. Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. Biomed Pharmacother. 2009 Nov;63 (9) :635-42.|[7] Pyrko P, et al. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res. 2007 Nov 15;67 (22) :10920-8. |[8] Alomar FA, et al. Efavirenz, atazanavir, and ritonavir disrupt sarcoplasmic reticulum Ca2+ homeostasis in skeletal muscles. Antiviral Res. 2021 Mar;187:104975. |[9] Robillard KR, et al. Role of P-glycoprotein in the distribution of the HIV protease inhibitor atazanavir in the brain and male genital tract. Antimicrob Agents Chemother. 2014;58 (3) :1713-22.